32 related articles for article (PubMed ID: 20726605)
1. Novel saturated 1,2,4-trioxanes and their antimalarial activity against multidrug resistant Plasmodium yoelii nigeriensis in Swiss mice model via oral route.
Kumari A; Yadav P; Rawat V; Maurya RA; Islam MS; Eldesoky GE; Puri SK; Verma VP
Bioorg Med Chem Lett; 2024 Aug; 108():129801. PubMed ID: 38777279
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the synthesis and antimalarial activity of 1,2,4-trioxanes.
Rathi K; Shukla M; Hassam M; Shrivastava R; Rawat V; Prakash Verma V
Bioorg Chem; 2024 Feb; 143():107043. PubMed ID: 38134523
[TBL] [Abstract][Full Text] [Related]
3. Identification of 3-((1-(Benzyl(2-hydroxy-2-phenylethyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamoyl)pyrazine-2-carboxylic Acid as a Potential Inhibitor of Non-Nucleosidase Reverse Transcriptase Inhibitors through InSilico Ligand- and Structure-Based Approaches.
Mathpal D; Almeleebia TM; Alshahrani KM; Alshahrani MY; Ahmad I; Asiri M; Kamal M; Jawaid T; Srivastava SP; Saeed M; Balaramnavar VM
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500699
[TBL] [Abstract][Full Text] [Related]
4. 3D QSAR pharmacophore modeling, in silico screening, and density functional theory (DFT) approaches for identification of human chymase inhibitors.
Arooj M; Thangapandian S; John S; Hwang S; Park JK; Lee KW
Int J Mol Sci; 2011; 12(12):9236-64. PubMed ID: 22272131
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates.
Bhattacharjee AK; Hartell MG; Nichols DA; Hicks RP; Stanton B; van Hamont JE; Milhous WK
Eur J Med Chem; 2004 Jan; 39(1):59-67. PubMed ID: 14987834
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-VeitÃa M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
8. Enantiomeric 1,2,4-trioxanes display equivalent in vitro antimalarial activity versus Plasmodium falciparum malaria parasites: implications for the molecular mechanism of action of the artemisinins.
O'Neill PM; Rawe SL; Borstnik K; Miller A; Ward SA; Bray PG; Davies J; Oh CH; Posner GH
Chembiochem; 2005 Nov; 6(11):2048-54. PubMed ID: 16222725
[TBL] [Abstract][Full Text] [Related]
9. Triple-layered QSAR studies on substituted 1,2,4-trioxanes as potential antimalarial agents: superiority of the quantitative pharmacophore-based alignment over common substructure-based alignment.
Gupta AK; Saxena AK
SAR QSAR Environ Res; 2013; 24(2):119-34. PubMed ID: 23194465
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling of substituted 1,2,4-Trioxanes for quantitative prediction of their antimalarial activity.
Gupta AK; Chakroborty S; Srivastava K; Puri SK; Saxena AK
J Chem Inf Model; 2010 Aug; 50(8):1510-20. PubMed ID: 20726605
[TBL] [Abstract][Full Text] [Related]
11. Endoperoxide antimalarials: development, structural diversity and pharmacodynamic aspects with reference to 1,2,4-trioxane-based structural scaffold.
Rudrapal M; Chetia D
Drug Des Devel Ther; 2016; 10():3575-3590. PubMed ID: 27843298
[TBL] [Abstract][Full Text] [Related]
12. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update.
Kumar S; Guha M; Choubey V; Maity P; Bandyopadhyay U
Life Sci; 2007 Feb; 80(9):813-28. PubMed ID: 17157328
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
